BIO Professional Development
Through a curated network of education alliance partners, BIO offers industry professionals executive training and development resources for accelerating career growth
Clinical Development 401: Phase IV
Clinical Development 401: Phase surveys the ongoing post-approval clinical assessments required by regulatory agencies. Learn how drug risk management is accomplished through detecting, assessing and reporting adverse effects using real-world data.
![bio-course-directory-image-3 (2).png](/sites/default/files/2021-01/bio-course-directory-image-3%20%282%29.png)
Clinical Development 401: Phase IV Course Trailer
Takeaways
- Purpose of Phase IV studies.
- Key limitations of pre-market studies and why post-market studies are an important complement to Phase I-III studies.
- Role of regulatory safety information reporting programs including MedWatch in US and EudraVigilance in Europe.
- In-depth look at Real-World Data (RWD) and Real-World Evidence (RWE) and their impact on safety.
- Identification of important real-world data sources
Download Course Syllabus
Clinical Development 401 Phase IV
Course offered by
![Courses offered by BiotechPrimer](/sites/default/files/2024-04/biotech-primer-2024-500px.png)
![](/act-root/bio/assets/images/icon/price_big.png)
Course Price:
$150 USD
![](/act-root/bio/assets/images/icon/bio_price_big.png)
BIO Member Price:
$120 USD
![](/act-root/bio/assets/images/icon/time_big.png)
Course Length:
50 minutes
![](/act-root/bio/assets/images/icon/level_big.png)
Course Level:
Advanced
![](/act-root/bio/assets/images/icon/completion_period_big.png)
Completion Period:
2 weeks
![](/act-root/bio/assets/images/icon/format_big.png)
Course Format:
On-Demand
Certificate Requirements
- View entire course
- Pass course exam with a 70 percent
- Complete the course evaluation